Tempest Therapeutics Appoints Troy M. Wagner as Vice President of Quality Assurance

Troy M. Wagner has been named Vice President of Quality Assurance at Tempest Therapeutics. Wagner has a wealth of expertise in overseeing quality control programs for international clinical trials, managing late-stage product development, and supporting international regulatory filings. Wagner's addition to the Tempest leadership team is a source of great excitement as the company advances towards the Phase 3 development of amezalpat, the main oncology candidate for liver cancer. Wagner brought more than 30 years of expertise in clinical compliance and quality to Tempest when he arrived in August of 2024. She has supported regulatory agency liaisons, handled compliance, quality assurance, and quality control at a number of pharmaceutical and device manufacturing facilities, and overseen the application of company quality standards.

Wagner has worked for a number of life sciences and pharmaceutical firms in a variety of compliance and quality assurance roles. Amezalpat, Tempest's top oncology candidate, has demonstrated encouraging clinical outcomes in liver cancer, indicating its potential to change the course of treatment for a notoriously difficult-to-treat disease.